文献速递白血病造血干细胞移植与细胞治疗

侵袭性NK细胞白血病治疗与预后进展:ANKL22研究结果

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.
PubMed 文献 · Leukemia · 2026-01-07

该多中心回顾性研究纳入108例可评估的侵袭性NK细胞白血病(ANKL)患者,分析2000至2021年间治疗与预后。中位总生存(OS)为5.5个月,2年OS率18.7%。SMILE方案组2年OS率30.1%,优于其他方案组的7.0%(P<0.001);接受异基因造血干细胞移植(HSCT)者2年OS率37.2%,优于未移植者的3.5%(P<0.001)。多因素分析证实SMILE方案和异基因HSCT为独立有利因素。

要点

  • ANKL预后极差,中位OS仅5.5个月,2年OS率18.7%。
  • SMILE方案诱导治疗较其他方案显著改善OS(2年OS率30.1% vs 7.0%)。
  • SMILE后桥接异基因HSCT可进一步改善生存(2年OS率37.2% vs 3.5%)。

核心结论

  • SMILE方案化疗后续贯异基因HSCT可能改善ANKL患者的结局。

研究设计与样本

  • 多中心回顾性研究,自71家机构收集2000至2021年诊断的126例ANKL患者,其中108例可评估分析。

主要发现

  • 可评估患者中位年龄49岁(范围17-90),男性63例;骨髓和外周血白血病细胞中位比例分别为19.7%和10.0%。
  • 一线方案包括SMILE(n=38,42%)、CHOP(类)(n=26,29%)、DeVIC(n=15,17%)及其他含左旋门冬酰胺酶方案(n=8,9%),总缓解率分别为66%、31%、33%和50%。
  • 中位OS为5.5个月,2年OS率为18.7%。
  • SMILE组2年OS率30.1%,优于其他方案组的7.0%(P<0.001);异基因HSCT组2年OS率37.2%,优于未移植组的3.5%(P<0.001)。
  • 多因素分析显示SMILE(HR 0.53,95%CI 0.31-0.88)和异基因HSCT(HR 0.33,95%CI 0.18-0.61)为独立有利因素。

临床怎么用

  • 对符合条件的ANKL患者,可优先考虑含SMILE方案的诱导治疗,并在缓解后评估异基因HSCT。

局限性

  • 回顾性研究设计,样本量有限(可评估108例),可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aggressive NK-cell leukemia (ANKL) is a rare NK-cell leukemia characterized by, an aggressive clinical course, and frequent Epstein-Barr virus association. We retrospectively collected 126 ANKL patients diagnosed between 2000 and 2021 from 71 institutes; 108 were evaluable for analysis to characterize the recent advances. The median age was 49 years (range: 17-90), and 63 patients were male. The median percentage of leukemic cells in the bone marrow and peripheral blood was 19.7% and 10.0%, respectively. The first-line regimens included SMILE (n = 38, 42%), CHOP(-like) (n = 26, 29%), DeVIC (n = 15, 17%), and other L-asparaginase-containing regimens (n = 8, 9%), with the overall response rates of 66%, 31%, 33%, and 50%, respectively. Median overall survival (OS) was 5.5 months, with a 2-year OS of 18.7%. Patients treated with SMILE had significantly better OS than others (2-year OS 30.1% vs. 7.0%; P < 0.001). Prognosis further improved with allogeneic hematopoietic stem cell transplantation (HSCT) (2-year OS 37.2% vs 3.5%; P < 0.001). Multivariate analysis confirmed treatment with SMILE [hazard ratio (HR) 0.53, 95% confidential interval (CI) 0.31-0.88] and allogeneic HSCT (HR 0.33, 95% CI 0.18-0.61) as independent favorable factors. In conclusion, SMILE chemotherapy followed by allogeneic HSCT may improve outcomes in ANKL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Fujimoto A, Maeda T, Doki N, et al. Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study. Leukemia. 2026. PMID: 41501503. doi:10.1038/s41375-025-02854-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。